JOURNAL OF THE CZECH PEDIATRIC SOCIETY AND THE SLOVAK PEDIATRIC SOCIETY

Čes-slov Pediat 2026, 81(5):269-275 | DOI: 10.55095/CSPediatrie2026/017

The most common genes associated with epilepsy in children

Silvia Mináriková, Miriam Kolníková
Klinika detskej neurológie, Lekárska fakulta, Univerzita Komenského a Národný ústav detských chorôb, Bratislava

Epilepsy is one of the most common chronic neurological diseases worldwide. The International League Against Epilepsy classifies etiologies of epilepsy into six main categories: structural, genetic, infectious, metabolic, immune, and unknown. Currently, the genetic etiology is assumed to have the highest prevalence. This finding has been supported by a development of modern

genetic testing methods, which have enabled the identification of hundreds of genes associated with epilepsy and clarified their mechanisms of origin at the molecular level. Among the most common genes associated with epilepsies in childhood are SCN1A, KCNQ2, CDKL5, SCN2A, STXBP1, PCDH19, PRRT2, SCN8A, MECP2, and SLC2A1, with the first five accounting for more than half of genetically determined

cases. These genes can be divided into five groups based on their pathogenetic mechanisms: ion channel disorders (channelopathies), disorders of synaptic regulation, disorders of gene expression and regulation, metabolic disorders, and abnormalities in neuronal development and migration.

The aim of this article is to provide an overview of the most common genes associated with epilepsy in children, their pathogenetic mechanisms, and clinical correlations.

Keywords: epilepsy, etiology, genetics, genes, channelopathies

Received: December 17, 2025; Revised: March 4, 2026; Accepted: March 6, 2026; Published: July 1, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mináriková S, Kolníková M. The most common genes associated with epilepsy in children. Ces-slov Pediat. 2026;81(5):269-275. doi: 10.55095/CSPediatrie2026/017.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology 2017; 88: 296-303. Go to original source...
    2. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58(4): 512-521. Go to original source...
    3. Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975; 16(1): 1-66. Go to original source...
    4. Thomas RH, Berkovic SF. The hidden genetics of epilepsy - a clinically important new paradigm. Nat Rev Neurol 2014; 10(5): 283-92. Go to original source...
    5. Steinlein OK, Mulley JC, Propping P, et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995; 11(2): 201-3. Go to original source...
    6. Scheffer IE, Bhatia KP, Lopes-Cendes I, et al. Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain 1995; 118(Pt 1): 61-73. Go to original source...
    7. Carvill GL, Weckhuysen S, McMahon JM, et al. GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. Neurology 2014; 82(14): 1245-53. Go to original source...
    8. Lalioti MD, Scott HS, Buresi C, et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature 1997; 386(6627): 847-51. Go to original source...
    9. Ellis CA, Petrovski S, Berkovic SF. Epilepsy genetics: clinical impacts and biological insights. Lancet Neurol 2020; 19(1): 93-100. Go to original source...
    10. Symonds JD, McTague A. Epilepsy and developmental disorders: next generation sequencing in the clinic. Eur J Paediatr Neurol 2020; 24: 15-23. Go to original source...
    11. Martinez LA, Lai YC, Holder JL Jr, et al. Genetics in epilepsy. Neurol Clin 2021; 39(3): 743-777. Go to original source...
    12. Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol 1952; 117(4): 500-44. Go to original source...
    13. Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006; 9(9): 1142-9. Go to original source...
    14. Brunklaus A, Brünger T, Feng T, et al. The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. Brain 2022; 145(11): 3816-3831. Go to original source...
    15. Myers KA. SCN1A as a therapeutic target for Dravet syndrome. Expert Opin Ther Targets 2023; 27(6): 459-467. Go to original source...
    16. Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia 2022; 63(7): 1761-1777. Go to original source...
    17. Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356(9242): 1638-42. Go to original source...
    18. Devinsky O, Cross JH, Laux L, et al. Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017; 376(21): 2011-2020. Go to original source...
    19. Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2019; 394(10216): 2243-2254. Go to original source...
    20. ClinicalTrials.gov. Study of STK-001 in Children and Adolescents With Dravet Syndrome (MONARCH). Dostupné na: https://clinicaltrials.gov/study/NCT04442295 [cit. 2025-02-10].
    21. ClinicalTrials.gov. Open-Label Extension Study of STK-001 in Children and Adolescents With Dravet Syndrome (SWALLOWTAIL). Dostupné na: https://clinicaltrials.gov/study/NCT04740476 [cit. 2025-02-10].
    22. ClinicalTrials.gov. Study of Gene Therapy for Drug-resistant Focal Epilepsy (NCT05419492). Dostupné na: https://clinicaltrials.gov/study/NCT05419492 [cit. 2025-02-10].
    23. Scalmani P, Rusconi R, Armatura E, et al. Effects in neocortical neurons of mutations of the Na(v)1.2 Na+ channel causing benign familial neonatal-infantile seizures. J Neurosci 2006; 26(40): 10100-9. Go to original source...
    24. Rusina E, Simonti M, Duprat F, et al. Voltage-gated sodium channels in genetic epilepsy: up and down of excitability. J Neurochem 2024; 168(12): 3872-3890. Go to original source...
    25. Gardella E, Becker F, Møller RS, et al. Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation. Ann Neurol 2016; 79(3): 428-36. Go to original source...
    26. Maljevic S, Lerche H. Potassium channels: a review of broadening therapeutic possibilities for neurological diseases. J Neurol 2013; 260(9): 2201-11. Go to original source...
    27. Zheng Y, Chen J. Voltage-gated potassium channels and genetic epilepsy. Front Neurol 2024; 15: 1466075. Go to original source...
    28. Lepeta K, Lourenco MV, Schweitzer BC, et al. Synaptopathies: synaptic dysfunction in neurological disorders - a review from students to students. J Neurochem 2016; 138(6): 785-805. Go to original source...
    29. Scorrano G, Di Francesco L, Di Ludovico A, et al. Exploring the landscape of pre- and post-synaptic pediatric disorders with epilepsy: a narrative review on molecular mechanisms involved. Int J Mol Sci 2024; 25(22): 11982. Go to original source...
    30. Mercimek-Andrews S. STXBP1 encephalopathy with epilepsy. In: Adam MP, Feldman J, Mirzaa GM, et al. (ed.). GeneReviews®. Seattle (WA): University of Washington, Seattle 1993-2025. Dostupné na: https://www.ncbi.nlm.nih.gov/books/NBK396561/
    31. Xian J, Parthasarathy S, Ruggiero SM, et al. Assessing the landscape of STXBP1-related disorders in 534 individuals. Brain 2022; 145(5): 1668-1683. Go to original source...
    32. Yang K, Quiroz V, Ebrahimi-Fakhari D. PRRT2-related disorder. In: Adam MP, Feldman J, Mirzaa GM, et al. (ed.). GeneReviews®. Seattle (WA): University of Washington, Seattle 1993-2025. Dostupné na: https://www.ncbi.nlm.nih.gov/books/NBK475803/
    33. Ebrahimi-Fakhari D, Saffari A, Westenberger A, et al. The evolving spectrum of PRRT2-associated paroxysmal diseases. Brain 2015; 138(Pt 12): 3476-95. Go to original source...
    34. Heron SE, Ong YS, Yendle SC, et al. Mutations in PRRT2 are not a common cause of infantile epileptic encephalopathies. Epilepsia 2013; 54(5): e86-9. Go to original source...
    35. Gerosa L, Francolini M, Bassani S, et al. The role of protocadherin 19 (PCDH19) in neurodevelopment and in the pathophysiology of early infantile epileptic encephalopathy-9 (EIEE9). Dev Neurobiol 2019; 79(1): 75-84. Go to original source...
    36. Samanta D. PCDH19-related epilepsy syndrome: a comprehensive clinical review. Pediatr Neurol 2020; 105: 3-9. Go to original source...
    37. Bernardo P, Cuccurullo C, Rubino M, et al. X-linked epilepsies: a narrative review. Int J Mol Sci 2024; 25(7): 4110. Go to original source... Go to PubMed...
    38. Benke TA, Demarest S, Angione K, et al. CDKL5 deficiency disorder. In: Adam MP, Feldman J, Mirzaa GM, et al. (ed.). GeneReviews®. Seattle (WA): University of Washington, Seattle 1993-2025. Dostupné na: https://www.ncbi.nlm.nih.gov/books/NBK602610/
    39. Lamb YN. Ganaxolone: first approval. Drugs 2022; 82(8): 933-940. Go to original source...
    40. Neul JL, Kaufmann WE, Glaze DG, et al. RettSearch Consortium. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 2010; 68(6): 944-50. Go to original source...
    41. Seidner G, Alvarez MG, Yeh JI, et al. GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet 1998; 18(2): 188-91. Go to original source...
    42. Wang D, Pascual JM, Yang H, et al. Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol 2005; 57(1): 111-8. Go to original source...
    43. Klepper J, Leiendecker B. GLUT1 deficiency syndrome - 2007 update. Dev Med Child Neurol 2007; 49(9): 707-16. Go to original source...
    44. Veneruzzo GM, Loos MA, Armeno M, et al. Glucose transporter type 1 deficiency syndrome: clinical aspects, diagnosis, and treatment. Arch Argent Pediatr 2023; 121(1): e202202677.
    45. Schwantje M, Verhagen LM, van Hasselt PM, et al. Glucose transporter type 1 deficiency syndrome and the ketogenic diet. J Inherit Metab Dis 2020; 43(2): 216-222. Go to original source...
    46. Man A, Di Scipio M, Grewal S, et al. The genetics of tuberous sclerosis complex and related mTORopathies: current understanding and future directions. Genes (Basel) 2024; 15(3): 332. Go to original source...
    47. Striano P, Minassian BA. From genetic testing to precision medicine in epilepsy. Neurotherapeutics 2020; 17(2): 609-615. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content